Innate Pharma Dividends
| IPHA Stock | USD 1.74 0.08 4.82% |
As of February 15, 2026, Dividend Yield is expected to decline to 0. In addition to that, Dividend Payout Ratio is expected to decline to -0.04. Innate Pharma's past performance could be the main factor of why investors trade Innate Pharma stock today. Investors should clearly understand every aspect of the Innate Pharma dividend schedule, including its future sustainability, and how it might impact an overall investment strategy. This tool is helpful to digest Innate Pharma's dividend schedule and payout information. Innate Pharma dividends can also provide a clue to the current valuation of Innate Pharma.
| Last Reported | Projected for Next Year | ||
| Dividend Payout Ratio | (0.04) | (0.04) | |
| Dividend Paid And Capex Coverage Ratio | (20.28) | (21.30) |
Investing in stocks that pay dividends is one of many strategies that are good for long-term investments. Ex-dividend dates are significant because investors in Innate Pharma must own a stock before its ex-dividend date to receive its next dividend.
Innate Pharma Dividends Paid Over Time
Today, most investors in Innate Pharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Innate Pharma's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's dividends paid growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Innate Pharma dividends paid as a starting point in their analysis.
The total amount of dividends that a company has paid out to its shareholders over a specific period. Dividends Paid |
| Timeline |
Innate Pharma Historical Dividend Yield Growth
A solid dividend growth pattern of Innate Pharma could indicate future dividend growth is likely, which can signal long-term profitability for Innate Pharma. When investors calculate the dividend yield growth rate, they can use any interval of time they wish. They may also calculate the dividend yield growth rate using the least-squares method or simply take an annualized figure over a given time period. Dividend Yield is Innate Pharma dividend as a percentage of Innate Pharma stock price. Innate Pharma dividend yield is a measure of Innate Pharma stock productivity, which can be interpreted as interest rate earned on an Innate Pharma investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share. Dividend Yield |
| Timeline |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Innate Pharma. Market participants price Innate higher when confident in its future expansion prospects. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Innate Pharma assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth (0.75) | Earnings Share (0.65) | Revenue Per Share | Quarterly Revenue Growth (0.61) | Return On Assets |
The market value of Innate Pharma is measured differently than its book value, which is the value of Innate that is recorded on the company's balance sheet. Investors also form their own opinion of Innate Pharma's value that differs from its market value or its book value, called intrinsic value, which is Innate Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Innate Pharma's market value can be influenced by many factors that don't directly affect Innate Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Innate Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Innate Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Innate Pharma's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.